All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Medicines Discovery Catapult, Crown Bioscience partner to develop integrated translational biology platform for radiopharmaceuticals
Research collaboration, radiopharmaceuticals, drug discovery, translational biology, co-development - Read more

Uni-Bio Science, Kexing Biopharm partner on Teriparatide osteoporosis drug commercialization across six international markets
Licensing deal, commercialization, osteoporosis, international markets, milestone payments - Read more

THE GOOD
Clinical Trials

Galimedix's oral amyloid-targeting therapy GAL-101 advances to Ph2 fundraising after successful Alzheimer's disease safety trial
Small molecule, neurological, Alzheimer's disease, amyloid beta, blood-brain barrier, oral therapy - Read more

FORE Biotherapeutics' Ph1/2a data shows plixorafenib delivers 5+ year responses in BRAF-altered thyroid cancer patients
Small molecule, cancer, kinase inhibitor, thyroid cancer, BRAF inhibitor, targeted therapy - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Earnings & Finances

KalVista's new hereditary angioedema drug Ekterly reports $1.4M in sales after July FDA approval
Small molecule, rare disease, hereditary angioedema, revenue impact, financial - Read more [Paywall]

THE GOOD
Fundraises

Lila Sciences moves towards $300M+ Series A, scaling "scientific superintelligence" at $1B+ valuation
AI/ML platform, platform technology, autonomous science, platform-enabled - Read more [Paywall]

THE GOOD
Lawsuits

Gilead wins whistleblower lawsuit over hepatitis C kickback allegations after $202M HIV settlement
Small molecule, infectious disease, legal, kickback allegations - Read more

THE BAD
Investments

Eli Lilly pauses UK biotech incubator amid concerns over NHS pricing and industry environment
Strategic, operational, biotech incubator, pharmaceutical investment, regional development, market access - Read more

AstraZeneca pauses $271M Cambridge expansion, joining Merck & Co. and Eli Lilly in UK pharma exodus
Strategic, financial, operational, investment - Read more

THE BAD
Market Reports

ABPI report reveals UK pharma sector's declining competitiveness amid Merck & Co.'s London R&D cancellation
Pharma industry, regulatory, strategic, competitive, operational - Read more

THE BAD
Politics & Policy

Novartis loses court appeal challenging Medicare drug price negotiation program under Inflation Reduction Act
Regulatory policy, pharmaceutical industry, legal challenge, government pricing - Read more

THE UGLY
Politics & Policy

Vaccine stocks drop as Trump officials plan to link COVID-19 shots to child deaths at CDC meeting
mRNA vaccine, infectious disease, regulatory, political influence, stock market impact - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here